ArticleInternational journal of cardiology. Heart & vasculature2025
Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a major risk factor for thromboembolic events, with left atrial thrombus (LAT) formation occurring despite oral anticoagulant (OAC) therapy in some patients. Direct oral anticoagulants (DOACs) have demonstrated efficacy in preventing thrombosis; however, their role in LAT resolution compared to warfarin remains unclear. Methods: This retrospective, multicenter study analyzed 260 AF patients with transesophageal echocardiography (TEE)-confirmed LAT among 17,436 AF patients who underwent TEE. Patients were categorized into DOAC and warfarin groups. LAT resolution, ischemic stroke/systemic embolism, major bleeding, and all-cause death were evaluated. The warfarin group was further stratified by time in therapeutic range (TTR) (<60 % and ≥ 60 %), and the DOAC group by dose (standard and low). Results: During a median follow-up of 386 [367, 413] days, LAT resolution was achieved in 62 % of patients, significantly higher in the DOAC group (74 % vs. 54 %, P = 0.001). Standard-dose DOACs had the highest resolution rates, while TTR < 60 % had the lowest (79 % vs. 49 %). DOACs were independently associated with higher LAT resolution (OR = 2.91 [1.32-6.38], P = 0.008) and fewer bleeding events (OR = 0.26 [0.08-0.80], P = 0.019). Conclusions: DOAC therapy was associated with higher LAT resolution rates and showed a fewer bleeding events compared to warfarin. DOACs may serve as first-line therapy for LAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.